Clinical trials in Loures – page 7

658 clinical trials in Loures, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Loures at a glance

658

clinical trials

Research sites0

Quick filters

658 trials in Loures

Open in trial search

Conjunctivitis allergic+1

Recruiting

Study of Grass Pollen Extract and Olive Pollen Extract for Patients with Hay Fever and Asthma caused by Grass and Olive Pollen Allergies

Investigational

Study of Grass Pollen Extract and Olive Pollen Extract for Patients with Hay Fever and Asthma caused by Grass and Olive Pollen Allergies

Investigational

Portugal

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dactylis glomerata pollen, depigmented polymerized extract
Sponsor:LETI Pharma S.L.U.

Contact Research Centre

Interstitial lung disease+1

Recruiting

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Liquidia Technologies Inc.

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:ABBV-142
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

Registered drugNo placebo

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Cedazuridine
Sponsor:Fundacion Pethema

Contact Research Centre

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Letrozole
Sponsor:Olema Pharmaceuticals Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Kura Oncology Inc.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Tirzepatide
Sponsor:Eli Lilly & Co.

Contact Research Centre

Obsessive-compulsive disorder

Recruiting

A study testing the safety and effectiveness of BP1.

Investigational

A study testing the safety and effectiveness of BP1.

Investigational

Portugal

Participants:18–64 years · 65+ years
Sponsor:Bioprojet Pharma

Contact Research Centre

Cardiac failure+1

Recruiting

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo

A study of finerenone with standard treatment for children and young adults from birth to 18 years with heart failure and left ventricular systolic dysfunction

InvestigationalNo placebo

Portugal

Participants:0–17 years · 18–64 years
Substances:Finerenone
Sponsor:Bayer AG

Contact Research Centre

Cardiac failure+1

Recruiting

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational

A study of finerenone added to standard treatment in children aged 6 months to under 18 years with heart failure and reduced left heart pumping function

Investigational

Portugal

Participants:0–17 years
Substances:Finerenone
Sponsor:Bayer AG

Contact Research Centre

HER2 positive endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Alpha-1 antitrypsin deficiency

Recruiting

A study comparing under-the-skin and into-the-vein alpha1-proteinase inhibitor treatment in patients with alpha1-antitrypsin deficiency

InvestigationalNo placebo

A study comparing under-the-skin and into-the-vein alpha1-proteinase inhibitor treatment in patients with alpha1-antitrypsin deficiency

InvestigationalNo placebo

Portugal

Participants:18–64 years · 65+ years
Sponsor:Grifols Therapeutics LLC

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Loures

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, particularly exploring new therapies for HER2-positive and hormone receptor-positive variants. Studies include novel combinations of targeted therapies and immunotherapy approaches.

Advanced breast cancer therapies
HER2-positive treatment strategies
Non-small cell lung cancer interventions

Research includes evaluation of drugs like trastuzumab deruxtecan and combination therapies targeting specific cancer mutations.

02 Neurological Disorders

Comprehensive studies investigating treatments for multiple sclerosis and neurodegenerative conditions. Research focuses on both relapsing and progressive forms of MS, along with early-stage Alzheimer's disease.

Multiple sclerosis therapies
Alzheimer's disease treatments
Cognitive function studies

Trials evaluate medications like ocrelizumab and semaglutide for various neurological conditions.

03 Inflammatory Conditions

Advanced research into inflammatory bowel diseases, including studies on Crohn's Disease and Ulcerative Colitis. Trials evaluate novel therapeutic approaches and combination treatments.

Crohn's Disease management
Ulcerative Colitis treatments
Combination therapy approaches

Studies investigate medications such as risankizumab and ozanimod for long-term disease management.

Back to Portugal All countries